A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

  1. Goeldner, C.
  2. Kishnani, P.S.
  3. Skotko, B.G.
  4. Casero, J.L.
  5. Hipp, J.F.
  6. Derks, M.
  7. Hernandez, M.-C.
  8. Khwaja, O.
  9. Lennon-Chrimes, S.
  10. Noeldeke, J.
  11. Pellicer, S.
  12. Squassante, L.
  13. Visootsak, J.
  14. Wandel, C.
  15. Fontoura, P.
  16. d’Ardhuy, X.L.
  17. De La Torre Fornell, R.
  18. Glue, P.
  19. Hoover-Fong, J.
  20. Uhlmann, S.
  21. Malagón Valdez, J.
  22. Marshall, A.
  23. Martinón-Torres, F.
  24. Redondo-Collazo, L.
  25. Rodriguez-Tenreiro, C.
  26. Marquez Chin, V.
  27. Michel Reynoso, A.G.
  28. Mitchell, E.A.
  29. Slykerman, R.F.
  30. Wouldes, T.
  31. Loveday, S.
  32. Moldenhauer, F.
  33. Novell, R.
  34. Ochoa, C.
  35. Rafii, M.S.
  36. Rebillat, A.-S.
  37. Sanlaville, D.
  38. Sarda, P.
  39. Shankar, R.
  40. Pulsifer, M.
  41. Evans, C.L.
  42. Silva, A.M.
  43. McDonough, M.E.
  44. Stanley, M.
  45. McCary, L.M.
  46. Vicari, S.
  47. Wilcox, W.
  48. Zampino, G.
  49. Zuddas, A.
  50. Alle Autoren anzeigen +
Zeitschrift:
Journal of Neurodevelopmental Disorders

ISSN: 1866-1955,  1866-1947

Datum der Publikation: 2022

Ausgabe: 14

Nummer: 1

Art: Artikel

DOI: 10.1186/S11689-022-09418-0 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus